Results 91 to 100 of about 69,031,262 (351)

Experimental therapies under investigation for COVID-19

Journal of Community Hospital Internal Medicine Perspectives, 2021
Coronavirus Disease 2019, caused by the virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is a pandemic first discovered in Wuhan, China which has claimed over 1.7 million lives to date across the globe as of 24 December 2020.
Reshma Golamari, Neeru Kapoor, Tanuja Devaraj, Nitasa Sahu, Courtney Kramer, Rohit Jain   +5 more
doaj   +1 more source

Ivermectin: Evaluation of Efficacy and Safety in COVID-19

Безопасность и риск фармакотерапии, 2022
The search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2.
E. V. Shubnikova, N. A. Susekova, T. M. Bukatina, M. S. Galenko, A. A. Druzhinina   +4 more
doaj   +1 more source

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.

BioScience Trends, 2020
The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China.
Jian-Jun Gao, Zhenxue Tian, Xu Yang
semanticscholar   +1 more source

Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19

, 2021
Publisher Copyright: © 2021 Elsevier Inc. All rights reserved.Peer reviewedThe current COVID-19 pandemic has spread rapidly worldwide and has challenged fragile health care systems, vulnerable socioeconomic conditions, and population risk factors, and ...
Brenda Rojas Román, Del-Aguila-Arcentales, Shyla, Aldo Alvarez-Risco, Christian R. Mejia, Alvarez-Risco, Aldo, Palmer J. Hernández-Yépez, Yáñez, Jaime A., Chung, Sun Ah, Román, Brenda Rojas, Inga-Berrospi, Fiorella, Sun Ah Chung, Franko O. Garcia-Solorzano, Hernández-Yépez, Palmer J., Mejia, Christian R., Garcia-Solorzano, Franko O., Shyla Del-Aguila-Arcentales, Jaime A. Yáñez, Fiorella Inga-Berrospi   +17 more
core   +1 more source

Remdesivir in The Treatment of COVID-19

AJN, American Journal of Nursing, 2021
According to this study: The antiviral remdesivir is superior to placebo in the treatment of patients hospitalized with COVID-19.A variety of therapeutic approaches are needed to continue to improve outcomes in COVID-19 patients.
openaire   +2 more sources

Antihistamines as an Early Treatment for COVID-19

SSRN Electronic Journal, 2022
Infection with SARs-COV-2 results in COVID-19 disease. Between March 2020 and August 2021, 468 COVID-19 patients confirmed by PCR or antigen test, in Yepes, Spain, received early treatment with antihistamines, adding azithromycin in selected cases. The primary endpoint is the hospitalization rate of COVID-19 patients, and the secondary endpoints are ...
Juan Ignacio Morán Blanco, Judith A. Alvarenga Bonilla, Philip Fremont-Smith, Karina Villar Gómez de las Heras   +3 more
openaire   +3 more sources

Parents of Youth With Cancer Report on Their Psychosocial Care: iSTEPPP Survey Finds Alignment and Gaps With Standards

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The Standards for Psychosocial Care for Children with Cancer and Their Families guide the provision of comprehensive psychosocial care. Parallel to research characterizing implementation of the Standards from the perspective of providers, this study examines implementation of the Standards from the perspective of parents of youth ...
Emily M. Pariseau, Kimberly Buff, Michele A. Scialla, Kimberly S. Canter, Lori Wiener, Victoria Sardi‐Brown, Julia B. Tager, Kamyar Arasteh, Anne E. Kazak   +8 more
wiley   +1 more source

A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

, 2021
BACKGROUND: Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19. METHODS: We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 ...
DiCioccio, A. Thomas, Saggar, Suraj, Sivapalasingam, Sumathi, Aberg, Judith A., Kampman, Wendy, Ferreira, Manuel A., Kosmicki, Jack A., Parrino, Jani, Boyapati, Anita, Criner, Gerard, Hosain, Romana, Labriola-Tompkins, Emily, Akinlade, Bolanle, Brown, Samuel M., Weinreich, David M., Bhore, Rafia, Ng Gong, Michelle, Horowitz, Julie E., Hajizadeh, Negin, Sobieszczyk, Magdalena E., Park, William, Gulabani, Daya, Yancopoulos, George D., Mahmood, Adnan, Lederer, David J., Sperber, Steven J., Musser, Bret, Stein, David K., Baras, Aris, Giannelou, Angeliki, Menon, Vidya, Somersan-Karakaya, Selin, O’Brien, Meagan, Purcell, Lisa A., Nivens, Michael C., Herman, Gary, Kowal, Bari, Waldron, Alpana, Braunstein, Ned, Ramesh, Divya   +39 more
core   +1 more source

Forecasting the Dialysis Burden in Japan: Validation‐Based Projections of Prevalence and Incidence Through 2050

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Japan has one of the highest dialysis prevalence rates worldwide and a shrinking, aging population. Whether dialysis burden has entered a sustained post‐peak phase or whether recent declines partly reflect pandemic‐related disruptions remains uncertain.
Hatice Şahin, Berrak Itır Aylı, Nüket Paksoy   +2 more
wiley   +1 more source

Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second Wave in 2021 – A Preliminary Report from a Single Hospital

Clinical Ophthalmology, 2021
Ritu Arora,1 Ruchi Goel,1 Samreen Khanam,1 Sumit Kumar,1 Shalin Shah,1 Sonam Singh,1 Mohit Chhabra,1 Ravi Meher,2 Nita Khurana,3 Tanu Sagar,4 Suresh Kumar,5 Sandeep Garg,5 Jyoti Kumar,6 Sonal Saxena,4 Rashmi Pant7 1Department of Ophthalmology, Guru Nanak
Arora R, Goel R, Khanam S, Kumar S, Shah S, Singh S, Chhabra M, Meher R, Khurana N, Sagar T, Kumar S, Garg S, Kumar J, Saxena S, Pant R   +14 more
doaj